Humacyte, Inc.
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $406.00K | $-0.16 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $753.00K | $-0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $301.00K | $-0.24 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $0.28 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | Before market open | – | $-0.16 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | – | $-0.33 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 22, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
Press releases
Announcements Humacyte filed with the SEC
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte, Inc. Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte, Inc. Announces Pricing of Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in
Other events · EX-99.1 to Form 8-K
Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
commercialize our bioengineered acellular tissue engineered vessels (“ATEV s”) in the United States under the brand name Symvess in vascular trauma repair; the
Results of operations · Other events · EX-99.1 to Form 8-K
has provided the following updates to its risk factors set forth under the heading “Risk Factors” in the Company’s Annual
Results of operations · Other events · EX-99.2 to Form 8-K
Announces Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Announces P ricing of $60.0 Million Oversubscribed Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Statement on Recent Attacks
Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Statement on New York Times Article
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Proposed Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte, Inc. Announces Pricing of Public
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Humacyte Announces Pricing of $15.0 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte Third Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Announces Pricing of $30.0 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV TM ) BLA for the Treatment of Vascular Trauma
Results of operations · Other events · EX-99.1 to Form 8-K
Humacyte Second Quarter 2024 Financial Results and Business Update
Results of operations · Other events · EX-99.2 to Form 8-K
Humacyte First Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Universally Implantable Regenerative Human Tissue 1 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
Other events · EX-99.1 to Form 8-K
Humacyte Third Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Second Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Humacyte Completes Enrollment in Phase 2/3 Trial of
Other events · EX-99.1 to Form 8-K
Humacyte First Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K